OBJECTIVE： To evaluate the effectiveness and safety of rolapitant combined with 5-HT3 receptor antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting systematically， and to provide evidence-based reference in clinic. METHODS： Retrieved from CJFD， VIP， Wanfang Database， PubMed， EMBase and Cochrane Library， randomized controlled trials （RCTs） about rolapitant+5-HT3 receptor antagonist+ dexamethasone （trial group） vs. placebo combined with 5-HT3 receptor antagonist+dexamethasone （control group） for the prevention of chemotherapy-induced nausea and vomiting. Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation with Cochrane system evaluator manual 5.1.0. RESULTS： A total of 3 literatures were included， involving 4 RCTs and 2 583 patients. The results of Meta-analysis were as follows： complete remission rate [acute stage： RR＝1.10，95％CI（1.02，1.19），P＝0.01；delay stage： RR＝1.18，95％CI（1.11，1.25），P＜0.001；overall stage： RR＝1.19，95％CI（1.12，1.26），P＜0.001] and the proportion of patients with functional indexes of vomiting living＞108 [RR＝1.10，95％CI（1.04，1.16），P＜0.001] in trial group were significantly higher than control group， with statistical significance. There was no statistical significance in the incidence of ADR between 2 groups[RR＝1.10，95％CI（0.82，1.47），P＝0.52]. CONCLUSIONS： Rolapitant combined with 5-HT3 receptor antagonist and dexamethasone can effectively prevent and relieve chemotherapy-induced nausea and vomiting， and improve the quality of life with good safety.